President, Research & Development, Takeda Pharmaceutical Company

Andrew Plump, M.D., Ph.D., is the President, Research & Development of Takeda Pharmaceutical Company Limited and serves as a member of the company’s Board of Directors. His career spans nearly 30 years in the pharmaceutical industry and academia and his experience encompasses early research through regulatory approval and patient access. Dr. Plump’s approach toward drug research and development is reflected in a virtuous cycle of “bench to bedside to bench” learning. He is a true translational physician-scientist, with deep knowledge in biomedical research, experimental medicine, early development, genomics and biomarkers and a history of scientific contributions in neuroscience, cardiovascular and metabolic diseases.

Throughout his career, Dr. Plump has been motivated to make an impact for patients by translating groundbreaking science into the practice of healthcare. He is regarded as a multi-dimensional leader who is passionate about leading diverse, cross-functional teams and nurturing a high-performing culture to achieve a shared mission, innovate for patients and change health for the better. Currently, Dr. Plump leads Takeda’s modern, world-class, global R&D organization of ~5,000 employees.

Together with an outstanding team, Dr. Plump has orchestrated the prioritization of Takeda’s modality-diverse pipeline that is delivering innovative, life-changing medicines in Oncology, Rare Diseases, Neuroscience and Gastroenterology to patients in two distinct waves. First, through FY2024, Takeda anticipates delivering 12 new molecular entities with the potential for 14 launches that represent best-in-class-or first-in-class therapies. Beyond FY2024, Takeda’s R&D engine is advancing a steady stream of next-generation therapies based on human-validated targets, a robust network of outstanding partnerships and new platform capabilities in cell therapy, gene therapy and data sciences.

Prior to Takeda, Dr. Plump served as Senior Vice President, Research & Translational Medicine, Deputy to the President of R&D at Sanofi, based in Paris, France. Prior to Sanofi, Dr. Plump served as Vice President, Worldwide Cardiovascular (CV) Research Head at Merck, where he had direct responsibility for CV research, preclinical development and translational sciences.

Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics with Dr. Jan Breslow at Rockefeller University and his B.S. from the Massachusetts Institute of Technology (MIT). He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Dr. Plump trained as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an Adjunct Clinical Instructor in the Department of Medical Genetics.


17 November 2020